The assay is for Niemann Pick Type C, a rare neurodegenerative disease characterized by lipid storage in the endosomal/lysosomal system. Treatment options are limited due to difficulty accessing the central nervous system. Mutations causing the disease are typically missense mutations affecting the NPC1 protein. The assay is a cell-based luciferase reporter assay designed to identify up-regulators of the mutant NPC1 promoter. Is the molecule effective to this assay?